[Retracted] A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia

Figure 5

Forest plot depicting the adverse event rates of PCSK9 monoclonal antibody on FH compared with placebo controls on adverse events, serious events, and laboratory adverse events: (a) any adverse events; (b) serious adverse events; (c) leading to treatment discontinuation; (d) adjudicated cardiovascular events; (e) nervous system disorders; (f) creatine kinase (); (g) headache; (h) nasopharyngitis; (i) abnormal liver function risk (AST/); (j) injection site reactions.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)